<DOC>
	<DOCNO>NCT00976170</DOCNO>
	<brief_summary>This phase I trial study safety best dose GC33 Sorafenib combination patient advance metastatic liver cancer .</brief_summary>
	<brief_title>Study GC33 Sorafenib Combination Advanced Metastatic Liver Cancer ( Hepatocellular Carcinoma )</brief_title>
	<detailed_description>This Phase I open-label dose escalation study GC33 combination Sorafenib patient advance metastatic HCC . This study design evaluate safety , tolerability , pharmacokinetics , efficacy . Enrollment proceed maximum tolerate dose ( MTD ) recommend Phase II dose establish .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Signed write Institutional Review Board/Ethical Committee approve informed consent form . Male female ≥18 year old . Life expectancy ≥3 month . ECOG Performance Status 01 . Histologically confirm hepatocellular carcinoma . Not candidate curative treatment . ChildPugh A Hematological , Biochemical Organ Function : AST ( SGOT ) : ≤5.0 × ULN , ALT ( SGPT ) : ≤5.0 × ULN , Total Bilirubin : ≤1.5mg/dL , Platelets : ≥100,000/μL , Absolute Neutrophil Count : ≥1,500/μL , Serum creatinine : ≤2.0 × ULN , PTINR : ≤2.0 Ability provide tumor tissue sample either : A formalin fix paraffin embed block sample within 12 month prior inform consent HCC diagnosis Undergo biopsy confirm HCC diagnosis Measurable disease . ChildPugh B C Patient take Sorafenib previously . Difficulty inability swallow pill . Pregnant lactate woman woman childbearing potential men childbearing potential willing use effective mean contraception . Patients know positive Human immunodeficiency virus infection . Active infectious disease require treatment except hepatitis B C. Other malignancy within last 5 year . History transplantation ( organ , bone marrow transplantation , Peripheral blood stem cell transplantation , etc. ) . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirements.. Patients know brain metastasis central nervous system disease/disorders . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmhg diastolic blood pressure &gt; 90 mmHg , despite optimal medical management . Nontumor relate thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 3 , hemorrhage/bleeding event ≥ CTCAE Grade 4 within 4 week first dose study drug . Serious nonhealing wound , ulcer , bone fracture . Patients receive major surgery , local therapy HCC , chemotherapy , radiotherapy , hormonetherapy , immunotherapy , another investigational drug within 4 week prior Day 1 ( 6 week nitrosoureas , mitomycin , bevacizumab ; 1 week tumor biopsy ) . Patients receive follow treatment within 2 week prior Day 1 : Anticoagulant thrombolytic agent therapeutic purpose , Systemic antiviral therapy hepatitis C Interferon therapy hepatitis B , Blood transfusion include blood product Known history hypersensitivity similar agent . Patients receive medication substance inducer CYP3A4 ineligible : rifampin , St. John 's wort , phenytoin , carbamazepine , phenobarbital dexamethasone . Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol requirement and/or followup procedure ; condition discuss patient trial entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Advanced metastatic HCC</keyword>
</DOC>